Eleftheria Tsakalozou from the Office of Generic Drugs illustrates how modeling and simulation approaches such as physiologically based pharmacokinetic (PBPK) modeling can be used to advance drug development and support alternative bioequivalence approaches for generic dermatology drugs. Model-informed dose selection for dermal open flow microperfusion studies assessing the cutaneous pharmacokinetics of test and reference products and justifying acceptable differences in physical and structural composition between test and reference products using in silico in vitro permeation testing methods are highlighted.
.

For more information, visit https://www.fda.gov/drugs/regulatory-education-industry-advancing-innovative-science-generic-drug-development-workshop
______________________________________________
FDA CDER's Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human pharmaceuticals and clinical research.

Upcoming training – https://www.fda.gov/cdersbia
SBIA Listserv – https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_idUSFDA_352
SBIA 2020 Playlist – https://www.youtube.com/playlist?listPLey4Qe-UxcxZiTopt4biuIyxmUQJDkaWb
SBIA LinkedIn – https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance
SBIA Training Resources – https://www.fda.gov/cderbsbialearn
Twitter – https://twitter.com/FDA_Drug_Info
Email – [email protected]
Phone – (301) 796-6707 I (866) 405-5367

Please take the opportunity to connect and share this video with your friends and family if you find it helpful.